ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1070

Evaluating & Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients

John Hickernell1 and Zineb Aouhab2, 1Loyola Univeristy Medical Center, Chicago, IL, 2Loyola University Medical Center, Oak Brook, IL

Meeting: ACR Convergence 2024

Keywords: practice guidelines, pulmonary, quality of care, Scleroderma, Systemic, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) has been shown to decrease mortality. The American College of Radiology, European Society of Cardiology/European Respiratory Society, and 6th World Symposium of PH all recommend yearly screening with 1) Pulmonary Function Testing (PFT) with diffusing capacity for carbon monoxide (DLCO), 2) Transthoracic Echocardiogram (TTE), and 3) B-natriuretic peptide (BNP). Clinician adherence to these screening guidelines is not well established, with one study showing rates as low as 34% (Pauling JD et al.). In our retrospective study, we aim to assess adherence to screening guidelines in our medical center to develop a quality improvement intervention for enhanced timely screening.

 

Methods: Patient charts were reviewed from Loyola University Medical Center, a quartenary care health system in the Chicagoland area. Patients were selected by meeting the following criteria: 1) patients received a diagnosis of SSc by a rheumatologist (using ICD-10 diagnostic codes), 2) were at least 18 years old at diagnosis, 3) were seen by a rheumatologist in our outpatient clinics from January 1, 2018 to December 31, 2022, and 4) did not have a diagnosis of pulmonary hypertension before January 1, 2018.

Charts were reviewed for demographic data, outpatient rheumatology appointments, PFTs, TTEs, and BNPs. Full compliance was defined as an appointment with a completed PFT, TTE, and BNP in the 12 months prior or 6 months after said visit. Ever compliant was defined as a patient having just one of these tests completed. Using these definitions allowed us to not underestimate compliance in situations where a patient did not follow with a rheumatologist all 5 years of the study period (e.g. changed care to an outside provider, established care late, had inconsistent follow-ups).

 

Results: Seventy-nine patients were identified to have met all criteria as above. Demographically, 87% of patients were female, 54% White, 14% Black, 25% Latino, 1% Asian, and 5% other. Over five years, these patients had a total of 484 appointments. Seventy-five percent (363) of all appointments had at least one screening test (PFT, TTE, BNP) completed 12 months prior or 6 months after the visit. However, only 10.7% of all appointments had all three tests completed, as recommended by international guidelines. Analyzing each test separately, only 58.1% (281), 61.2% (296), and 15.7% (76) of appointments had a corresponding PFT, TTE, and BNP, respectively (Figure 1).

 

Conclusion: Our results show that our medical center is not immune to the internationally reported low rates of guideline-directed screening for PH in SSc patients. These results are the impetus for our quality improvement project currently in progress at our institution. Interventions include an educational session by a PH expert and an order set on our EMR for seamless point-of-care ordering. We hope to share post-intervention results soon, as we all tackle this specialty-wide gap in guideline-care delivery.

Supporting image 1

Figure 1: Percentage compliance of appointments having at least one test completed (Ever) or all three test completed (Fully) 12 months prior or 6 months after said visit. Compliance is also stratified by test: PFT, TTE, BNP.


Disclosures: J. Hickernell: None; Z. Aouhab: None.

To cite this abstract in AMA style:

Hickernell J, Aouhab Z. Evaluating & Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/evaluating-improving-adherence-to-pulmonary-hypertension-screening-in-systemic-sclerosis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-improving-adherence-to-pulmonary-hypertension-screening-in-systemic-sclerosis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology